APLT vs. CDMO, PBYI, GTHX, RIGL, PRTA, CPRX, RCKT, ZLAB, GLPG, and KROS
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Avid Bioservices (CDMO), Puma Biotechnology (PBYI), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Prothena (PRTA), Catalyst Pharmaceuticals (CPRX), Rocket Pharmaceuticals (RCKT), Zai Lab (ZLAB), Galapagos (GLPG), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
Applied Therapeutics (NASDAQ:APLT) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Applied Therapeutics has a net margin of 0.00% compared to Avid Bioservices' net margin of -13.10%. Avid Bioservices' return on equity of -8.78% beat Applied Therapeutics' return on equity.
Avid Bioservices received 296 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
Applied Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are owned by institutional investors. 8.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Avid Bioservices shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Avid Bioservices has higher revenue and earnings than Applied Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Applied Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 157.01%. Avid Bioservices has a consensus price target of $14.50, suggesting a potential upside of 79.23%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Therapeutics is more favorable than Avid Bioservices.
In the previous week, Avid Bioservices had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 6 mentions for Avid Bioservices and 5 mentions for Applied Therapeutics. Avid Bioservices' average media sentiment score of 1.12 beat Applied Therapeutics' score of 1.09 indicating that Avid Bioservices is being referred to more favorably in the news media.
Summary
Applied Therapeutics and Avid Bioservices tied by winning 9 of the 18 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
